NRx Pharmaceuticals (NRXP) Q4 2025 earnings summary

Executive summary

• 2025 marked a transformative year with reduced operating expenses, $7.8 million in cash, and elimination of all convertible debt.

• Advanced key drug candidates KETAFREE, NRX-100, and NRX-101 toward FDA approval, with commercial operations targeted by year-end 2026.

• Opened and expanded HOPE Therapeutics clinics, reporting high clinical response rates for neuroplastic therapies in depression and PTSD.

• Revenue generation began with clinic acquisitions and expansion of the HOPE Therapeutics network.

• Established a nationwide partnership to expand neuroplastic therapy clinics and services.

Financial highlights

• Loss from operations reduced by $2.3 million to $16.2 million for 2025, primarily due to lower R&D expenses.

• Research and development expense decreased by $2.4 million to $3.8 million year-over-year.

• General and administrative expense decreased by $0.4 million to $13.1 million.

• Ended 2025 with $7.8 million in cash and cash equivalents.

Outlook and guidance

• Management expects current cash, revenue growth, and ATM activities to support operations through 2026.

• Pro forma profitability targeted by year-end 2026, contingent on success of at least one drug program.

• Expects FDA approval of at least one new drug (preservative-free ketamine) in Q3 2026.

• Plans to expand the clinical network and pursue further clinic acquisitions.